USDA to grant Bulgaria's Huvepharma exclusive license for African swine fever vaccine

The prospective exclusive license will be royalty-bearing, the USDA's Agricultural Research Service agency said in a statement.

"The prospective exclusive license may be granted unless, within thirty (30) days from the date of this published Notice, the Agricultural Research Service receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7," the agency said in a statement.

The final date for submitting comments is May 22.

Huvepharma develops both human and animal health products. The company also manufactures and markets enzymes for food, feed and industrial applications.

Huvepharma's manufacturing subsidiary - Biovet, is headquartered in Peshtera, Bulgaria and has three production units in the country and two facilities in the USA. Huvepharma has representative offices and subsidiaries in Bulgaria, Belgium, Poland, China, Taiwan, Thailand, USA, Russia, India, Brazil and Turkey.